.jpg?format=webp&width=780)
The article discusses a phase 3 trial of the monoclonal antibody dupilumab for the treatment of eosinophilic esophagitis. Dupilumab blocks interleukin-4 and interleukin-13 signaling. While historically topical glucocorticoids have been used as first-line treatment, the trial only compared dupilumab with a placebo, and it is unknown whether dupilumab is superior to glucocorticoids in treating eosinophilic esophagitis. Additionally, the incidence of histologic remission was lower in patients who received dupilumab.
Like
Save
Share